Clinical profiles and treatment evaluation of tuberculous uveitis in tertiary eye hospital in Jakarta
DOI:
https://doi.org/10.13181/mji.oa.257609Keywords:
clinical medicine, tuberculosis, uveitisAbstract
BACKGROUND Tuberculous uveitis (TU) is the second most common cause of intraocular inflammation in Indonesia. This study aimed to determine the clinical characteristics of patients with TU and the therapies used at Jakarta Eye Center (JEC) Eye Hospitals and Clinics.
METHODS This retrospective descriptive study included 265 eyes of 189 patients diagnosed with TU at the JEC Eye Hospital and Clinics between January 2018 and June 2022. This study used secondary data collected by reviewing patient medical records, including clinical profiles and therapeutic characteristics recorded during treatment. Data were analyzed using SPSS software version 24 for Windows.
RESULTS Most patients (68.3%) complained of blurry vision, and 99 (52.4%) underwent an interferon-gamma release assay. HIV infection was present in 8.5% of the patients, and 4.8% had diabetes mellitus. Among them, 27 (14.3%) had posterior uveitis, 34 (18.0%) had anterior uveitis, and 127 (67.2%) had panuveitis. The most common feature of inflammation was vitreous opacity. Visual acuity (VA) improved to 0.4 (1.11) after treatment. The most common complication was cataract formation (71 patients). In the group that received combination therapy with systemic steroids and anti-tuberculosis treatment (ATT), 58.7% had a better VA.
CONCLUSIONS TU has several clinical manifestations. Treatment with systemic steroids, ATT, or a combination of both can improve VA.
Downloads
References
Sève P, Cacoub P, Bodaghi B, Trad S, Sellam J, Bellocq D, et al. Uveitis: diagnostic work-up. A literature review and recommendations from an expert committee. Autoimmun Rev. 2017;16(12):1254-64. https://doi.org/10.1016/j.autrev.2017.10.010
Tsirouki T, Dastiridou A, Symeonidis C, Tounakaki O, Brazitikou I, Kalogeropoulos C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26(1):2−16. https://doi.org/10.1080/09273948.2016.1196713
Krishna U, Ajanaku D, Denniston AK, Gkika T. Uveitis: a sight-threatening disease which can impact all systems. Postgrad Med J. 2017;93(1106):766-73. https://doi.org/10.1136/postgradmedj-2017-134891
La Cava M, Bruscolini A, Sacchetti M, Pirraglia MP, Moramarco A, Marenco M, et al. Clinical and epidemiological study on tubercular uveitis in a tertiary eye care centre in Italy. J Ophthalmol. 2020;2020:4701820. https://doi.org/10.1155/2020/4701820
Ministry of Health of the Republic of Indonesia. [National guidelines for medical services in tuberculosis management]. Jakarta: Ministry of Health of the Republic of Indonesia; 2020. Indonesian.
World Health Organization (WHO). Global tuberculosis programme: TB reports [Internet]. Geneva: World Health Organization (WHO); 2021 [cited 2024 Jan 12]. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports.
Gogia V, Venkatesh P, Garg SP, Takkar B, Sheemar A. Patterns of uveitis in patients with proven systemic (pulmonary and extrapulmonary) tuberculosis. Int Ophthalmol. 2019;39(8):1665-7. https://doi.org/10.1007/s10792-018-0989-9
Shah JS, Shetty N, Shah SK, Shah NK. Tubercular uveitis with ocular manifestation as the first presentation of tuberculosis: a case series. J Clin Diagnostic Res. 2016;10(3):NR01-3. https://doi.org/10.7860/JCDR/2016/16219.7375
Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509-16. https://doi.org/10.1016/j.ajo.2005.03.057
Llorenç V, Benejam G, Mesquida M, Sainz de la Maza M, Molins B, Alba C, et al. Antituberculous treatment itself might prevent visual impairment in presumed tuberculosis-related uveitis. Ocul Immunol Inflamm. 2020;28(1):103-10. https://doi.org/10.1080/09273948.2018.1541326
Fernandes P, Ma Y, Gaeddert M, Tsacogianis T, Marques-Rodrigues P, Fregona G, et al. Sex and age differences in Mycobacterium tuberculosis infection in Brazil. Epidemiol Infect. 2018;146(12):1503-10. https://doi.org/10.1017/S0950268818001450
Nora RL, Sitompul R, Susiyanti M, Edwar L, Sjamsoe S. Clinical characteristic and therapy results of presumed ocular tuberculosis and their relation to HIV status. Med J Indones. 2012;21(4):214-9. https://doi.org/10.13181/mji.v21i4.509
Alfaray RI, Mochtar NM, Zharfan RS, Subkhan M. Occupational status and educational stage as a valuable factors affecting knowledge and perception level of Indonesian tuberculosis patient. Med Leg Updat. 2021;21(2):1000-8. https://doi.org/10.37506/mlu.v21i2.2814
Alli HD, Ally N, Mayet I, Joseph L, Omar S, Madhi S. Treatment outcome of tubercular uveitis in a high TB and HIV setting: a prospective cohort study. Clin Ophthalmol. 2021;15:4839-46. https://doi.org/10.2147/OPTH.S342268
Ang M, Hedayatfar A, Wong W, Chee SP. Duration of anti-tubercular therapy in uveitis associated with latent tuberculosis: a case-control study. Br J Ophthalmol. 2012;96(3):332-6. https://doi.org/10.1136/bjophthalmol-2011-300209
Semilan HM, Abugad HA, Mashat HM, Abdel Wahab MM. Epidemiology of tuberculosis among different occupational groups in Makkah region, Saudi Arabia. Sci Rep. 2021;11(1):12764. https://doi.org/10.1038/s41598-021-91879-9
Puzyreva LV, Safonov AD, Lebedev OI, Mordyk AV. [Ocular tuberculosis]. Vestn Oftalmol. 2016;132(3):103-7. Russian. https://doi.org/10.17116/oftalma20161323103-107
Câmara SN, Barbosa Júnior JB, Barbosa KC. Anterior uveitis as a manifestation of ocular tuberculosis. Rev Bras Oftalmol. 2019;78(3):195-8. https://doi.org/10.5935/0034-7280.20190128
Ang M, Hedayatfar A, Zhang R, Chee SP. Clinical signs of uveitis associated with latent tuberculosis. Clin Exp Ophthalmol. 2012;40(7):689-96. https://doi.org/10.1111/j.1442-9071.2012.02766.x
Tomkins-Netzer O, Leong BC, Zhang X, Lightman S, McCluskey PJ; Sydney-London Latent Ocular TB Study Group. Effect of antituberculous therapy on uveitis associated with latent tuberculosis. Am J Ophthalmol. 2018;190:164−70. https://doi.org/10.1016/j.ajo.2018.03.032
Krassas N, Wells J, Bell C, Woodhead M, Jones N. Presumed tuberculosis-associated uveitis: rising incidence and widening criteria for diagnosis in a non-endemic area. Eye (Lond). 2018;32(1):87-92. https://doi.org/10.1038/eye.2017.152
Setyaningrum R, Zubaidah T, Anhar VY. Correlation between gender, age, education level, and working status with anti-tuberculosis drug uses (OATS) in patients with lung TB in Indonesia 2013. Int J Chem Mater Sci. 2018;1(1):7-13. https://doi.org/10.31295/ijcms.v1n1.3
Koller K, Ricci LH, Lindoso JA, Lindoso AA, Muccioli C. Clinical description and treatment of patients with presumed ocular tuberculosis in São Paulo, Brazil. Rev Bras Oftalmol. 2019;78(6):384-8.
Putera I, Schrijver B, Ten Berge JC, Gupta V, La Distia Nora R, Agrawal R, et al. The immune response in tubercular uveitis and its implications for treatment: from anti-tubercular treatment to host-directed therapies. Prog Retin Eye Res. 2023;95:101189. https://doi.org/10.1016/j.preteyeres.2023.101189
Betzler BK, Putera I, Testi I, La Distia Nora R, Kempen J, Kon OM, et al. Anti-tubercular therapy in the treatment of tubercular uveitis: a systematic review and meta-analysis. Surv Ophthalmol. 2023;68(2):241-56. https://doi.org/10.1016/j.survophthal.2022.10.001
Agrawal R, Testi I, Bodaghi B, Barisani-Asenbauer T, McCluskey P, Agarwal A, et al. Collaborative ocular tuberculosis study consensus guidelines on the management of tubercular uveitis-report 2: guidelines for initiating antitubercular therapy in anterior uveitis, intermediate uveitis, panuveitis, and retinal vasculitis. Ophthalmology. 2021;128(2):277-87. https://doi.org/10.1016/j.ophtha.2020.06.052
La Distia Nora R, Sitompul R, Bakker M, Susiyanti M, Edwar L, Sjamsoe S, et al. Tuberculosis and other causes of uveitis in Indonesia. Eye (Lond). 2018;32(3):546-54. https://doi.org/10.1038/eye.2017.231
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Ni Made Widya Mahayani, Made Susiyanti, Soedarman Sjamsoe, Anna Nur Utami
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.
